Healthcare / Medical Instruments & SuppliesCboe UK
$13.85
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-5.1M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$49M
P/E
N/A
•EV/EBITDA
6279.5x
↑ROE
-23.7%
↓Gross Margin
31.4%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-5.7%
FCF CAGR
—
FCF margin
-4.3%
FCF / Net income
0.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $117.3M · net income $-22.3M · FCF $-5.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $117.3M | $117.3M | $116.7M | $116.1M | $140.0M |
| Net Income | $-22.3M | $-22.3M | $-193000.00 | $244000.00 | $14.3M |
| EBITDA | $972000.00 | $972000.00 | $8.7M | $8.1M | $31.1M |
| EPS | -0.05 | -0.05 | -0.00 | 0.00 | 0.03 |
| Gross Margin | 31.4% | 31.4% | 32.8% | 32.7% | 36.5% |
| Operating Margin | 1.6% | 1.6% | 2.3% | 0.4% | 8.1% |
| Net Margin | -19.0% | -19.0% | -0.2% | 0.2% | 10.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.08 | 0.09 | 0.08 |
| Current Ratio | 1.85 | 1.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.1M | $-5.1M | $133000.00 | $-7.3M | $2.3M |
| Returns | |||||
| ROE | -23.7% | -23.7% | -0.2% | 0.2% | 11.3% |
| Valuation | |||||
| EV/EBITDA | 6279.54 | 6279.54 | 1032.46 | — | — |
| P/B | 65.07 | 65.07 | 75.18 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 0.5% | 0.5% | 0.5% | -17.1% | — |
| EPS Growth | -10120.0% | -10120.0% | -183.3% | -98.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7668.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.05
Residual
+7668.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.